Intrinsic value of Voyager Therapeutics - VYGR

Previous Close

$11.18

  Intrinsic Value

$1.43

stock screener

  Rating & Target

str. sell

-87%

Previous close

$11.18

 
Intrinsic value

$1.43

 
Up/down potential

-87%

 
Rating

str. sell

We calculate the intrinsic value of VYGR stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.4

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  16
  25
  37
  54
  77
  105
  142
  186
  239
  302
  375
  459
  553
  658
  773
  900
  1,036
  1,183
  1,340
  1,506
  1,682
  1,868
  2,062
  2,266
  2,479
  2,700
  2,931
  3,172
  3,422
  3,681
Variable operating expenses, $m
  63
  98
  146
  212
  299
  411
  552
  725
  933
  1,178
  1,463
  1,788
  2,156
  2,565
  3,016
  3,508
  4,041
  4,614
  5,225
  5,875
  6,561
  7,284
  8,043
  8,837
  9,667
  10,532
  11,433
  12,370
  13,344
  14,357
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  63
  98
  146
  212
  299
  411
  552
  725
  933
  1,178
  1,463
  1,788
  2,156
  2,565
  3,016
  3,508
  4,041
  4,614
  5,225
  5,875
  6,561
  7,284
  8,043
  8,837
  9,667
  10,532
  11,433
  12,370
  13,344
  14,357
Operating income, $m
  -47
  -73
  -109
  -158
  -222
  -306
  -410
  -539
  -694
  -876
  -1,088
  -1,330
  -1,603
  -1,907
  -2,242
  -2,609
  -3,005
  -3,431
  -3,885
  -4,368
  -4,879
  -5,416
  -5,981
  -6,571
  -7,188
  -7,831
  -8,501
  -9,198
  -9,923
  -10,676
EBITDA, $m
  -44
  -69
  -103
  -149
  -210
  -289
  -388
  -509
  -655
  -828
  -1,028
  -1,257
  -1,515
  -1,802
  -2,119
  -2,465
  -2,840
  -3,242
  -3,672
  -4,128
  -4,611
  -5,119
  -5,652
  -6,210
  -6,793
  -7,401
  -8,034
  -8,692
  -9,377
  -10,089
Interest expense (income), $m
  0
  0
  0
  1
  3
  6
  9
  13
  19
  26
  34
  43
  54
  67
  81
  97
  115
  134
  155
  178
  201
  227
  254
  282
  311
  342
  375
  409
  444
  480
  519
Earnings before tax, $m
  -47
  -72
  -110
  -161
  -228
  -315
  -424
  -558
  -719
  -910
  -1,131
  -1,384
  -1,670
  -1,989
  -2,340
  -2,724
  -3,139
  -3,586
  -4,063
  -4,570
  -5,106
  -5,670
  -6,263
  -6,883
  -7,531
  -8,206
  -8,910
  -9,642
  -10,403
  -11,195
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -47
  -72
  -110
  -161
  -228
  -315
  -424
  -558
  -719
  -910
  -1,131
  -1,384
  -1,670
  -1,989
  -2,340
  -2,724
  -3,139
  -3,586
  -4,063
  -4,570
  -5,106
  -5,670
  -6,263
  -6,883
  -7,531
  -8,206
  -8,910
  -9,642
  -10,403
  -11,195

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  51
  79
  117
  170
  240
  331
  444
  583
  750
  947
  1,176
  1,438
  1,733
  2,062
  2,424
  2,820
  3,248
  3,708
  4,200
  4,722
  5,274
  5,855
  6,465
  7,103
  7,770
  8,465
  9,189
  9,943
  10,726
  11,540
Adjusted assets (=assets-cash), $m
  51
  79
  117
  170
  240
  331
  444
  583
  750
  947
  1,176
  1,438
  1,733
  2,062
  2,424
  2,820
  3,248
  3,708
  4,200
  4,722
  5,274
  5,855
  6,465
  7,103
  7,770
  8,465
  9,189
  9,943
  10,726
  11,540
Revenue / Adjusted assets
  0.314
  0.316
  0.316
  0.318
  0.321
  0.317
  0.320
  0.319
  0.319
  0.319
  0.319
  0.319
  0.319
  0.319
  0.319
  0.319
  0.319
  0.319
  0.319
  0.319
  0.319
  0.319
  0.319
  0.319
  0.319
  0.319
  0.319
  0.319
  0.319
  0.319
Average production assets, $m
  15
  23
  34
  49
  70
  96
  129
  169
  217
  275
  341
  417
  502
  598
  703
  818
  942
  1,075
  1,218
  1,369
  1,529
  1,698
  1,875
  2,060
  2,253
  2,455
  2,665
  2,883
  3,110
  3,346
Working capital, $m
  -21
  -33
  -49
  -72
  -101
  -139
  -186
  -245
  -315
  -398
  -494
  -603
  -727
  -865
  -1,018
  -1,184
  -1,364
  -1,557
  -1,763
  -1,982
  -2,214
  -2,458
  -2,714
  -2,982
  -3,262
  -3,554
  -3,858
  -4,174
  -4,503
  -4,845
Total debt, $m
  -5
  20
  55
  103
  166
  247
  349
  474
  624
  802
  1,008
  1,243
  1,509
  1,805
  2,131
  2,487
  2,873
  3,287
  3,730
  4,199
  4,696
  5,219
  5,768
  6,343
  6,943
  7,568
  8,220
  8,898
  9,603
  10,336
Total liabilities, $m
  46
  71
  106
  153
  216
  297
  399
  524
  675
  852
  1,058
  1,294
  1,559
  1,855
  2,182
  2,538
  2,923
  3,338
  3,780
  4,250
  4,747
  5,270
  5,818
  6,393
  6,993
  7,619
  8,271
  8,949
  9,654
  10,386
Total equity, $m
  5
  8
  12
  17
  24
  33
  44
  58
  75
  95
  118
  144
  173
  206
  242
  282
  325
  371
  420
  472
  527
  586
  646
  710
  777
  847
  919
  994
  1,073
  1,154
Total liabilities and equity, $m
  51
  79
  118
  170
  240
  330
  443
  582
  750
  947
  1,176
  1,438
  1,732
  2,061
  2,424
  2,820
  3,248
  3,709
  4,200
  4,722
  5,274
  5,856
  6,464
  7,103
  7,770
  8,466
  9,190
  9,943
  10,727
  11,540
Debt-to-equity ratio
  -0.920
  2.580
  4.710
  6.040
  6.900
  7.470
  7.860
  8.130
  8.330
  8.470
  8.570
  8.650
  8.710
  8.760
  8.790
  8.820
  8.840
  8.860
  8.880
  8.890
  8.900
  8.910
  8.920
  8.930
  8.940
  8.940
  8.950
  8.950
  8.950
  8.960
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -47
  -72
  -110
  -161
  -228
  -315
  -424
  -558
  -719
  -910
  -1,131
  -1,384
  -1,670
  -1,989
  -2,340
  -2,724
  -3,139
  -3,586
  -4,063
  -4,570
  -5,106
  -5,670
  -6,263
  -6,883
  -7,531
  -8,206
  -8,910
  -9,642
  -10,403
  -11,195
Depreciation, amort., depletion, $m
  3
  4
  6
  9
  12
  17
  23
  30
  38
  48
  60
  73
  88
  105
  123
  143
  165
  189
  214
  240
  268
  298
  329
  361
  395
  431
  467
  506
  546
  587
Funds from operations, $m
  -44
  -68
  -104
  -152
  -216
  -298
  -401
  -528
  -681
  -861
  -1,071
  -1,311
  -1,582
  -1,884
  -2,217
  -2,580
  -2,974
  -3,397
  -3,849
  -4,330
  -4,837
  -5,372
  -5,934
  -6,521
  -7,135
  -7,776
  -8,442
  -9,136
  -9,858
  -10,607
Change in working capital, $m
  -8
  -12
  -16
  -22
  -29
  -38
  -47
  -58
  -70
  -83
  -96
  -110
  -124
  -138
  -152
  -166
  -180
  -193
  -206
  -219
  -232
  -244
  -256
  -268
  -280
  -292
  -304
  -316
  -329
  -342
Cash from operations, $m
  -36
  -57
  -87
  -130
  -186
  -260
  -354
  -470
  -611
  -779
  -975
  -1,201
  -1,458
  -1,746
  -2,064
  -2,414
  -2,794
  -3,204
  -3,643
  -4,110
  -4,606
  -5,128
  -5,678
  -6,253
  -6,855
  -7,484
  -8,138
  -8,820
  -9,529
  -10,266
Maintenance CAPEX, $m
  -2
  -3
  -4
  -6
  -9
  -12
  -17
  -23
  -30
  -38
  -48
  -60
  -73
  -88
  -105
  -123
  -143
  -165
  -189
  -214
  -240
  -268
  -298
  -329
  -361
  -395
  -431
  -467
  -506
  -546
New CAPEX, $m
  -6
  -8
  -11
  -15
  -20
  -26
  -33
  -40
  -48
  -57
  -66
  -76
  -86
  -95
  -105
  -115
  -124
  -133
  -143
  -151
  -160
  -168
  -177
  -185
  -193
  -202
  -210
  -218
  -227
  -236
Cash from investing activities, $m
  -8
  -11
  -15
  -21
  -29
  -38
  -50
  -63
  -78
  -95
  -114
  -136
  -159
  -183
  -210
  -238
  -267
  -298
  -332
  -365
  -400
  -436
  -475
  -514
  -554
  -597
  -641
  -685
  -733
  -782
Free cash flow, $m
  -44
  -67
  -103
  -151
  -215
  -298
  -403
  -533
  -689
  -874
  -1,090
  -1,337
  -1,617
  -1,929
  -2,274
  -2,652
  -3,062
  -3,503
  -3,974
  -4,475
  -5,006
  -5,565
  -6,152
  -6,767
  -7,410
  -8,081
  -8,779
  -9,506
  -10,262
  -11,047
Issuance/(repayment) of debt, $m
  -5
  25
  35
  48
  63
  81
  102
  125
  150
  177
  206
  236
  266
  296
  326
  356
  386
  414
  442
  470
  497
  523
  549
  575
  600
  626
  652
  678
  705
  733
Issuance/(repurchase) of shares, $m
  71
  75
  114
  166
  235
  324
  435
  572
  736
  929
  1,154
  1,410
  1,700
  2,022
  2,376
  2,763
  3,182
  3,632
  4,112
  4,622
  5,161
  5,728
  6,324
  6,947
  7,597
  8,276
  8,982
  9,717
  10,482
  11,276
Cash from financing (excl. dividends), $m  
  66
  100
  149
  214
  298
  405
  537
  697
  886
  1,106
  1,360
  1,646
  1,966
  2,318
  2,702
  3,119
  3,568
  4,046
  4,554
  5,092
  5,658
  6,251
  6,873
  7,522
  8,197
  8,902
  9,634
  10,395
  11,187
  12,009
Total cash flow (excl. dividends), $m
  23
  33
  46
  63
  83
  106
  134
  164
  197
  233
  270
  309
  349
  388
  428
  467
  506
  544
  580
  616
  652
  686
  720
  754
  787
  821
  855
  890
  925
  961
Retained Cash Flow (-), $m
  -71
  -75
  -114
  -166
  -235
  -324
  -435
  -572
  -736
  -929
  -1,154
  -1,410
  -1,700
  -2,022
  -2,376
  -2,763
  -3,182
  -3,632
  -4,112
  -4,622
  -5,161
  -5,728
  -6,324
  -6,947
  -7,597
  -8,276
  -8,982
  -9,717
  -10,482
  -11,276
Prev. year cash balance distribution, $m
  153
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  105
  -42
  -68
  -103
  -152
  -217
  -302
  -408
  -539
  -697
  -884
  -1,101
  -1,351
  -1,633
  -1,948
  -2,296
  -2,676
  -3,088
  -3,532
  -4,006
  -4,509
  -5,042
  -5,603
  -6,193
  -6,810
  -7,455
  -8,127
  -8,828
  -9,557
  -10,315
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  100
  -39
  -59
  -85
  -118
  -158
  -204
  -255
  -309
  -365
  -420
  -470
  -514
  -548
  -572
  -583
  -582
  -569
  -544
  -509
  -466
  -418
  -367
  -315
  -265
  -217
  -174
  -137
  -104
  -78
Current shareholders' claim on cash, %
  50.0
  7.7
  1.2
  0.2
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's pipeline consists of programs for CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington's disease; Friedreich's ataxia; frontotemporal dementia/Alzheimer's disease, and severe chronic pain. The Company's clinical candidate, VY-AADC01, is an adeno-associated virus (AAV) gene therapy product candidate, for the treatment of advanced Parkinson's disease. VY-AADC01 consists of the AAV2 capsid, which has been used in multiple AAV gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the aromatic L-amino acid decarboxylase (AADC) transgene. Its pipeline also includes VY-SOD101, VY-FXN01, VY-HTT01, VY-TAU01 and VY-NAV01.

FINANCIAL RATIOS  of  Voyager Therapeutics (VYGR)

Valuation Ratios
P/E Ratio -7.2
Price to Sales 20.4
Price to Book 2.1
Price to Tangible Book
Price to Cash Flow -6.8
Price to Free Cash Flow -6.1
Growth Rates
Sales Growth Rate -17.6%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 400%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0.2
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -19.1%
Ret/ On Assets - 3 Yr. Avg. -103.6%
Return On Total Capital -26.2%
Ret/ On T. Cap. - 3 Yr. Avg. -197.9%
Return On Equity -26.2%
Return On Equity - 3 Yr. Avg. 335%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -278.6%
EBITDA Margin - 3 Yr. Avg. -149.7%
Operating Margin -300%
Oper. Margin - 3 Yr. Avg. -141.2%
Pre-Tax Margin -285.7%
Pre-Tax Margin - 3 Yr. Avg. -154.1%
Net Profit Margin -285.7%
Net Profit Margin - 3 Yr. Avg. -154.1%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

VYGR stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the VYGR stock intrinsic value calculation we used $10.135 million for the last fiscal year's total revenue generated by Voyager Therapeutics. The default revenue input number comes from 0001 income statement of Voyager Therapeutics. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our VYGR stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for VYGR is calculated based on our internal credit rating of Voyager Therapeutics, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Voyager Therapeutics.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of VYGR stock the variable cost ratio is equal to 390%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for VYGR stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Voyager Therapeutics.

Corporate tax rate of 27% is the nominal tax rate for Voyager Therapeutics. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the VYGR stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for VYGR are equal to 90.9%.

Life of production assets of 5.7 years is the average useful life of capital assets used in Voyager Therapeutics operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for VYGR is equal to -131.6%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $134.051 million for Voyager Therapeutics - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 32.321 million for Voyager Therapeutics is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Voyager Therapeutics at the current share price and the inputted number of shares is $0.4 billion.

RELATED COMPANIES Price Int.Val. Rating
RGNX REGENXBIO 50.01 1.29  str.sell
CYTK Cytokinetics 8.00 15.12  str.buy
IONS Ionis Pharmace 56.17 6.10  str.sell
PTCT PTC Therapeuti 34.88 214.00  str.buy
BIIB Biogen 322.61 402.94  hold
ONCE Spark Therapeu 41.32 3.43  str.sell
ADVM Adverum Biotec 3.81 0.72  str.sell

COMPANY NEWS

▶ Voyager Therapeutics: 3Q Earnings Snapshot   [Nov-07-18 06:09PM  Associated Press]
▶ Voyager Therapeutics: 2Q Earnings Snapshot   [06:41PM  Associated Press]
▶ Benzinga Pro's 5 Stocks To Watch Today   [Jun-21-18 08:54AM  Benzinga]
▶ Voyager Therapeutics Announces Management Change   [May-29-18 04:30PM  GlobeNewswire]
▶ Voyager Therapeutics: 1Q Earnings Snapshot   [May-10-18 07:55AM  Associated Press]
▶ 4 Strong Buy Biotech Stocks Poised to Explode   [Mar-29-18 07:03AM  TheStreet.com]
▶ Voyager Therapeutics reports 4Q loss   [Mar-14-18 07:33AM  Associated Press]
▶ 3 Biotech Stocks That Soared This Week: Are They Buys?   [Feb-24-18 10:37AM  Motley Fool]
▶ How An AbbVie Deal Sent This Biotech Stock To A 2-Year High   [Feb-21-18 04:32PM  Investor's Business Daily]
▶ Voyager Therapeutics Announces CEO Succession Plan for 2018   [Jan-31-18 04:05PM  GlobeNewswire]
▶ Stocks Showing Market Leadership: Voyager Therapeutics Earns 91 RS Rating   [Jan-16-18 03:00AM  Investor's Business Daily]
▶ Voyager Therapeutics to Host R&D Day on November 16, 2017   [Nov-12-17 06:00PM  GlobeNewswire]
▶ Voyager Therapeutics reports 3Q loss   [Nov-02-17 05:36PM  Associated Press]
▶ Bad Luck Bites Biotech Analyst   [Oct-31-17 09:35AM  The Wall Street Journal]
▶ Who Really Owns Voyager Therapeutics Inc (VYGR)?   [Oct-30-17 06:41PM  Simply Wall St.]
▶ 8 Stocks for the Next Gene Revolution   [Sep-29-17 06:00AM  Investopedia]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.